Who Owns Genmab Company?

Genmab Bundle

Get Full Bundle:

	5 FORCES	$15	$10
	BCG	$15	$10
	CANVAS	$15	$10
	4P's MIX	$15	$10
	PESTLE	$15	$10
	SWOT	$15	$10

TOTAL:

ADD TO CART

Who Owns Genmab?

Understanding a company's ownership is key to grasping its trajectory. Genmab's journey began with its IPO in October 2000, raising DKK 1.56 billion and establishing it as a publicly traded entity.

This Danish biotechnology firm, founded in 1999, focuses on antibody therapeutics for cancer. Its vision is to create next-generation antibody medicines, aiming to transform cancer treatment. The company's commitment to innovation is evident in its ongoing research and development efforts, including advancements in areas like Genmab PESTEL Analysis.

As of 2024, Genmab is Europe's largest biotech by market cap, with revenues of DKK 21.526 billion and an anticipated 2025 revenue between USD 3.3 to USD 3.7 billion. This growth highlights its significant market presence and investor confidence.

Genmab A/S was co-founded in February 1999 by Florian Schönharting, Lisa N. Drakeman, Ph.D., and Jan G. J. van de Winkel, Ph.D. Florian Schönharting provided the initial seed investment, while Lisa Drakeman and Jan G. J. van de Winkel brought their expertise from the biotech sector, specifically from Medarex. This foundational collaboration set the stage for Genmab's future growth and development in the biotechnology industry.

The early ownership structure of Genmab was significantly influenced by its founding team and initial investors. Florian Schönharting, as the managing director of BankInvest Biomedical venture fund, was instrumental in providing the crucial seed capital. Lisa Drakeman's background at Medarex, an American biotech company, facilitated Genmab's establishment as a European spin-off, and Jan G. J. van de Winkel, who later became Genmab's CEO, brought extensive scientific leadership. The company's initial funding strategy, including a Series A round that raised $33.6 million in 1999 and an additional $13.2 million from Novo A/S, was vital for its product-focused development approach. While precise founder equity splits are not publicly disclosed, these early capital infusions and strategic alignments were foundational to shaping Genmab's ownership and enabling its rapid expansion within the biotechnology sector. Understanding these early dynamics is key to comprehending current Genmab ownership and who owns Genmab today.

Early Investment and Strategic Focus

Genmab's early financial backing was critical for its operational launch and strategic direction. The initial capital allowed the company to differentiate itself by focusing on product development rather than solely on technology platforms, a key strategic decision that influenced its trajectory.

• The company secured significant early funding, including a Series A round of $33.6 million in 1999.
• Novo A/S also contributed $13.2 million, further bolstering the company's financial foundation.
• This early capital was instrumental in establishing Genmab's product-focused development strategy.
• The company's early strategy distinguished it from its predecessor's emphasis on technology platforms.
• Research into the Growth Strategy of Genmab highlights the importance of these early decisions.

Genmab SWOT Analysis

• Complete SWOT Breakdown
• Fully Customizable
• Editable in Excel & Word
• Professional Formatting
• Investor-Ready Format

GET TEMPLATE ➔

Genmab's ownership structure has been shaped by key events, notably its Initial Public Offering (IPO) in October 2000, which raised DKK 1.56 billion. A subsequent public offering in January 2006 further bolstered its capital, bringing in DKK 800 million. The company's presence on both the Copenhagen Stock Exchange and the Nasdaq Global Select Market as an ADR under the ticker GMAB signifies its global investor base.

As of June 29, 2025, the top 25 Genmab company shareholders collectively hold 38.89% of the company's shares, indicating a significant concentration among major investors. Institutional investors play a crucial role, with their ownership of Genmab ADRs reaching 9.75% in February 2025. This trend is further supported by the increase in mutual fund holdings, which rose from 4.44% to 4.57% in the same month. The CEO, Jan G.J. van de Winkel, is a notable insider shareholder, possessing 1.03% of the company's shares, valued at approximately $149.22 million. This broad ownership base, heavily influenced by institutional investors, has been instrumental in funding Genmab's extensive research and development efforts and supporting its strategic growth into a fully integrated biotechnology firm.

Genmab's Shareholder Landscape

Understanding Genmab's ownership structure is key to grasping its strategic direction and financial stability. The company's evolution from its IPO to its current global presence highlights the importance of its diverse investor base.

• The top 25 shareholders own 38.89% of the company as of June 29, 2025.
• Institutional investors held 9.75% of Genmab ADRs in February 2025.
• Major institutional shareholders include AllianceBernstein L.P. and BlackRock Inc.
• CEO Jan G.J. van de Winkel holds a 1.03% stake in the company.
• The company's public and institutional ownership fuels its R&D pipeline.
• For a deeper dive into market dynamics, explore the Target Market of Genmab.

Genmab PESTLE Analysis

• Covers All 6 PESTLE Categories
• No Research Needed – Save Hours of Work
• Built by Experts, Trusted by Consultants
• Instant Download, Ready to Use
• 100% Editable, Fully Customizable

GET TEMPLATE ➔

Genmab's governance is led by its Board of Directors and Executive Committee. Deirdre P. Connelly currently serves as the Board Chair. The company's strategic direction and operational leadership are managed by the Executive Committee, which includes key figures in its biotechnology operations.

The voting power within Genmab appears to operate on a standard one-share-one-vote principle for its publicly traded shares, with no immediate indications of dual-class shares or special voting rights. CEO Jan G.J. van de Winkel holds a personal stake of 1.03% in the company, reflecting a significant but not dominant individual ownership. The company's leadership, with an average tenure of 6.6 years for the management team and 8.4 years for the board, emphasizes stability and continuity in its strategic vision to become a fully integrated biotech firm. Recent public records do not highlight any proxy battles or activist investor campaigns that have substantially altered the company's governance or decision-making processes.

Genmab's Shareholder Structure

Understanding Genmab's ownership structure is key to grasping its corporate governance and strategic direction. The company's publicly traded shares generally adhere to a one-share-one-vote system.

• CEO Jan G.J. van de Winkel holds 1.03% of Genmab's shares.
• The average tenure of the management team is 6.6 years.
• The average tenure of the board of directors is 8.4 years.
• No recent proxy battles or activist campaigns have been reported.
• The company aims to be a fully integrated biotech.

Genmab Business Model Canvas

• Complete 9-Block Business Model Canvas
• Effortlessly Communicate Your Business Strategy
• Investor-Ready BMC Format
• 100% Editable and Customizable
• Clear and Structured Layout

GET TEMPLATE ➔

Over the past few years, Genmab has actively managed its capital, including significant share buybacks, and has strategically expanded its business. The company's ownership structure is influenced by these actions and broader industry trends in institutional investment.

Genmab's recent developments reflect a dynamic approach to capital management and strategic growth. The company completed a substantial share buy-back program in June 2024, acquiring up to DKK 3.5 billion in shares, which resulted in 2,670,991 treasury shares, representing 4.04% of its total share capital. A subsequent buyback initiative, targeting up to 2.2 million shares, was initiated in March 2025 and concluded by the first half of the year. Financially, Genmab maintained a strong cash position of approximately $3 billion by the end of H1 2025. The acquisition of ProfoundBio for $1.8 billion in January 2024 significantly enhanced its cancer pipeline with advanced antibody-drug conjugates. Leadership also saw changes, with key appointments and departures occurring in 2024 and 2025, including the retirement of the Chief Legal Officer in July 2025. The company continues to foster strategic partnerships, maintaining 17 collaborations with both pharmaceutical and biotech firms, which are crucial for its commercialized products and royalty income. Genmab has reaffirmed its 2025 financial guidance, projecting revenues between USD 3.3 billion and USD 3.7 billion, driven by royalties and product sales, aiming for sustained double-digit growth.

Capital Management and Shareholder Value

Genmab's share buyback programs demonstrate a commitment to enhancing shareholder value. These actions can influence the Genmab company shareholders by reducing the number of outstanding shares, potentially increasing earnings per share.

Strategic Acquisitions and Pipeline Expansion

The acquisition of ProfoundBio for $1.8 billion in January 2024 significantly bolstered Genmab's pipeline. This move is indicative of the company's strategy to invest in innovative technologies to drive future growth and product development.

Institutional Ownership Trends

Institutional holdings in Genmab's ADRs reached 9.75% in February 2025, reflecting a broader trend of increasing institutional ownership in the biotechnology sector. This suggests growing confidence from major investors in the company's prospects.

Financial Outlook and Growth Drivers

Genmab has reaffirmed its 2025 revenue guidance between USD 3.3 billion and USD 3.7 billion. This projection is primarily supported by recurring royalties and product sales, underscoring the company's focus on sustainable revenue streams and its Marketing Strategy of Genmab.

Genmab Porter's Five Forces Analysis

• Covers All 5 Competitive Forces in Detail
• Structured for Consultants, Students, and Founders
• 100% Editable in Microsoft Word & Excel
• Instant Digital Download – Use Immediately
• Compatible with Mac & PC – Fully Unlocked

GET TEMPLATE ➔